Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia (AML) has passed a phase 3 test with a more than nine-month ...
A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in overall funding ...
TrimTech Therapeutics has been tapped by Biogen in a $411 million biobucks collaboration to develop protein degraders for ...
CG now plans to complete that expanded FDA submission by the end of 2027’s first quarter. Meanwhile, in intermediate ...
Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to ...
Eli Lilly has added another myelofibrosis (MF) play to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech ...
Flagship Pioneering has picked London as the site of the venture capital powerhouse’s first company-creation unit outside of ...
Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to ...
A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the ...
Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.
While Kyverna awaits an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy, the biotech ...
Tandem Diabetes Care has picked up FDA clearance of its Tandem Mobi system, a tubeless automated insulin delivery device cleared for up to seven days of wear . The new Tandem Mobi tubeless cartridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results